(3S)-3-methyloxan-3-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: (3S)-3-methyloxan-3-ol
• 化学式: C₆H₁₂O₂
• 分子量: 116.16
• InChiKey: JUQXHRNZEMUHEI-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS
  申请人：Repare Therapeutics Inc.

  公开号：US20210177856A1

  公开（公告）日：2021-06-17

  Disclosed are methods of treating a cancer in a subject using an ATR inhibitor and PARP inhibitor. wherein the cancer has been previously identified as a cancer having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or as an ALT+ cancer. Also disclosed are methods of inducing cell death in an aberrant cancer cell having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or an ALT+ cancer cell, by contacting the cell with an effective amount of an ATR inhibitor and PARP inhibitor.
• COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS
  申请人：Repare Therapeutics Inc.

  公开号：US20210277002A1

  公开（公告）日：2021-09-09

  Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
• [EN] SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS<br/>[FR] DÉRIVÉS 2-MORPHOLINOPYRIDINE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE KINASES ATR
  申请人：REPARE THERAPEUTICS INC

  公开号：WO2021012049A1

  公开（公告）日：2021-01-28

  Disclosed are compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein — is a single bond, and each Y is N or CR4; or — is absent, and each Y is NRY, carbonyl, or C(RY)2, wherein each R1 is H or optionally substituted C1-6 alkyl; R1 is optionally substituted C1-6 alkyl or H; R3 is optionally substituted C1-9 heteroaryl or optionally substituted C1-9 heteroarylC1-6 alkyl; each R4 is hydrogen, halogen, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, or optionally substituted C2-6 alkynyl; X is hydrogen or halogen; and R2 is as defined in claim 1. Also disclosed are pharmaceutical compositions containing the compounds of formula (I) and methods for their preparation. The compounds of formula (I) may be inhibitors of Ataxia-telangiectasia and RAD-3 -related protein kinase (ATR) and used for the treatment of diseases or conditions such as cancers.
• [EN] USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS<br/>[FR] UTILISATION D'INHIBITEURS D'ATR EN ASSOCIATION AVEC DES INHIBITEURS DE PARP
  申请人：REPARE THERAPEUTICS INC

  公开号：WO2021119523A1

  公开（公告）日：2021-06-17

  Disclosed are methods of treating a cancer in a subject using an ATR inhibitor and PARP inhibitor, wherein the cancer has been previously identified as a cancer having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or as an ALT+ cancer. Also disclosed are methods of inducing cell death in an aberrant cancer cell having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or an ALT+ cancer cell, by contacting the cell with an effective amount of an ATR inhibitor and PARP inhibitor.
• [EN] USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS FOR TREATING CANCER<br/>[FR] UTILISATION D'INHIBITEURS D'ATR EN ASSOCIATION AVEC DES INHIBITEURS DE PARP POUR LE TRAITEMENT DU CANCER
  申请人：[en]REPARE THERAPEUTICS INC.

  公开号：WO2022261777A1

  公开（公告）日：2022-12-22

  Disclosed are methods of treating a cancer and of inducing cell death in an aberrant cancel cell in a subject using a combination of an ATR inhibitor and PARP inhibitor, wherein the PARP inhibitor may be a compound of formula (III) or (IV), or a pharmaceutically acceptable salt thereof; and wherein the cancer/aberrant cell cancer has a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B and/or CDK12; or is an ALT+ cancer/cancer cell. In formula (III): X1and X2are each N or C(H); X3is N and C(R4), R4is H or fluoro; R1is C1-4alkyl or C1-4fluoroalkyl; R2is H, halo, C1-4alkyl, or C1-4fluoroalkyl; and R3is H or C1-4alkyl. In formula (IV): R1is H, C1-4alkyl, C3-6cycloalkyl, C1-4fluoroalkyl, and C1-4fliioroalkyloxy; R2is H, halo, C1-4alkyl, or C1-4fhioroalkyl; R3is H or C1-4alkyl; and R4is halo or C1-4alkyl.